Zusammenfassung
Endokrine Therapieoptionen haben beim rezeptorpositiven, d. h. östrogensensitiven Mammakarzinom einen hohen Stellenwert. Eingesetzt werden selektive Östrogenrezeptorhemmer, Antiöstrogene, Aromatasehemmer, Gestagene und GnRH-Agonisten. In der Regel werden diese langfristig eingesetzt, sodass deren Nebenwirkungsspektrum mit akuten und chronischen Begleiterscheinungen von großer Bedeutung ist. Aufgrund der antiendokrinen Wirkungsmechanismen stehen bei allen Substanzen in der Regel klimakterische Symptome sowie antiresorptive Effekte am Knochen (Zunahme des Frakturrisikos) im Vordergrund. In diesem Beitrag wird darüber hinaus auf weitere substanzspezifische unerwünschte Effekte eingegangen.
Abstract
Endocrine therapy options are very important in hormone receptor-positive, i.e., estrogen-sensitive, breast cancer. Selective estrogen receptor inhibitors, anti-estrogens, aromatase inhibitors, gestagens, and GnRH agonists are used. Normally, these forms of treatment are meant for long-term use. Therefore, tolerability, toxicity, and safety with acute and chronic side effects are of great importance. Due to the anti-endocrine mechanisms of all these substances, climacteric symptoms as well as antiresorptive effects in bones (increase in the risk of fracture) are the central side effects. Furthermore, undesirable effects specific for the substances are described in this article.
This is a preview of subscription content, log in via an institution to check access.
Literatur
ATAC Trialists‘ Group (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years‘ adjuvant treatment for breast cancer. Lancet 365:60–62
Choueiri TK, Alemany CA, Abou-Jawde RM, Budd GT (2004) Role of aromatase inhibitors in the treatment of breast cancer. Clin Therapeutics 26:1199–1214
Cohen I (2004) Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol 94:256–266
Coombes RC, Hall E, Gibson LJ et al. (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Eng J Med 350:1081–1092
Deitcher SR, Gomes MP (2004) The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer 101(3):439–449
Dombernowsky P, Smith I, Falkson G, Leonard R et al. (1998) Letrozole, a new aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453–464
Elisaf MS, Bairaktari ET, Nicolaides C et al. (2001) Effects of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 37:1510–1513
Fisher B, Costantino J, Redmond C et al. (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node negative brast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479
Gershanovich M, Chaudri HA, Campos D et al. (1998) Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2,5 mg daily, 0,5 mg daily and aminogluthethimide in postmenopausal women in advanced breast cancer. Ann Oncol 9:639–645
Goss PE, Ingle JN, Martino DO et al. (2003) A randomized trial of letrozole in postmenopausal women afer five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793–1802
Harper-Wynne C, Ross G, Sacks N et al. (2002) Effects of the aromatase inhibitor letrozole on breast cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev 11:614–621
Kaufmann M, Bajetta E, Dirix LY et al. (2000) Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 18:1399–1411
Kedar RP, Bourne TH, Powles T et al. (1994) Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 28; 343(8909):1318–1321
Lohrisch C, Paridaens R, Dirix LY et al. (2001) No adverse impact on serum lipids of the irreversible aromatase inactivator Aromasin (exemestan) in 1st line treatment of metastatic breast cancer: companion study to a European Organization of Research and Treatment of Cancer (Breast Group) trial with Pharmacias‘ Upjohn. Proc Am Soc Clin Oncol 20:43a
Osborne CK (1998) Tamoxifen in the treatment of breast cancer. New Engl J Med 339:1609–1617
Osborne CK, Elledge RM, Fuqua SAW (1996) Estrogen receptors in breast cancer therapy. Sci Med 3:32–41
Uziely B, Lewin A, Brufman G et al. (1993) The effect of tamoxifen on the endometrium. Breast Cancer Res Treat 26:101
Interessenkonflikt:
Keine Angaben
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Diesing, D., Friedrich, M. & von Otte, S. Nebenwirkungen der endokrinen Therapie beim Mammakarzinom. Gynäkologische Endokrinologie 3, 91–96 (2005). https://doi.org/10.1007/s10304-005-0109-6
Issue Date:
DOI: https://doi.org/10.1007/s10304-005-0109-6